GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines, today underscored the strategic significance of recent research supporting its Gedeptin platform's potential to enhance immune checkpoint inhibitor activity in checkpoint-resistant tumors. The company's update follows a peer-reviewed publication in JCI Insight titled “Broadening Activity of Checkpoint Blockade Agents by Intratumoral Nucleoside Cleavage,” which demonstrated that Gene-Directed Enzyme-Prodrug Therapy (GDEPT) could boost checkpoint inhibitor responses and activate systemic anti-tumor immunity in preclinical models of triple-negative breast cancer.
The findings come at a time when the oncology industry is increasingly focused on immune-priming strategies to overcome checkpoint resistance. Checkpoint inhibitors targeting PD-1 and PD-L1 have transformed cancer treatment, but many tumors—known as 'cold' tumors—remain unresponsive due to limited immune infiltration and immunosuppressive microenvironments. GeoVax recently explored this challenge in an Onco'Zine commentary by Chairman and CEO David Dodd, titled “The Cold Tumor Barrier: Why Promising Oncology Therapies Fail In Vivo – and What It Will Take to Overcome It.”
“One of the most significant challenges in oncology today is the cold tumor barrier,” said David Dodd. “Checkpoint inhibitors can be highly effective when sufficient immune activity already exists within a tumor. However, many tumors remain largely invisible to the immune system. The next major opportunity may lie in therapies capable of activating immune recognition and making these tumors more responsive to existing immunotherapies.”
GeoVax positions Gedeptin as a complementary approach, not a direct competitor to checkpoint inhibitors. The platform combines localized tumor destruction, bystander killing, tumor microenvironment remodeling, and immune activation. According to the company, these characteristics align with next-generation combination immunotherapy strategies. “The medical proposition is to improve responses where checkpoint inhibitors alone have not achieved their full potential; also representing a significant commercial opportunity with multiple partnering avenues,” Dodd added.
GeoVax's lead clinical focus for Gedeptin is a planned neoadjuvant study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin in combination with PD-1-based immunotherapy and standard of care in patients eligible for curative-intent surgery. The company considers this setting attractive due to tumor accessibility, integration of checkpoint inhibitors into standard care, and high unmet need. “As checkpoint inhibitors continue moving earlier in the treatment paradigm, opportunities are emerging for therapies designed to improve immune responsiveness before surgery and potentially improve long-term outcomes,” Dodd said.
Beyond head and neck cancer, GeoVax sees potential for Gedeptin across multiple solid tumor types where checkpoint inhibitors are standard but response rates remain suboptimal. The company's broader platform opportunity targets the growing industry emphasis on converting cold tumors to responsive ones. “The emerging data support continued evaluation of Gedeptin as a differentiated immune-priming platform designed to complement existing immunotherapies and potentially broaden the impact of checkpoint blockade across multiple tumor settings,” Dodd concluded.
